{"url_path":"/sec/ptnt/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A Risk Factors.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/911216/0001493152-26-022778-index.html","accession_number":"0001493152-26-022778","cik":"0000911216","ticker":"PTNT","issuer_name":"PALATIN TECHNOLOGIES INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/911216/0001493152-26-022778-index.html","primary_entity_key":"0000911216","primary_entity_name":"PALATIN TECHNOLOGIES INC"},"word_count":522,"has_tables":true,"body_markdown":"**Item\n1A. Risk Factors.**\n\n \n\nThis\nreport and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates,\nforecasts and projections about us, our future performance, our business, our beliefs, and our management’s assumptions. These\nstatements are not guarantees of future performance, and they involve certain risks, uncertainties and assumptions that are difficult\nto predict. You should carefully consider the risks and uncertainties facing our business.\n\n \n\nOther\nthan set forth below, there have been no material changes to our risk factors disclosed in Part I, Item 1A, of our Annual Report on Form\n10-K for the year ended June 30, 2025.\n\n \n\n**Inadequate\nfunding for the FDA, the SEC and other U.S. government agencies leading to government shut downs or other disruptions to these agencies’\nstaffing and operations could prevent new products and services from being developed or commercialized in a timely manner or otherwise\nprevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively\nimpact our operations.**\n\n** **\n\nThe\nability of the FDA to review and approve new products can be affected by a variety of factors, including government funding, ability\nto hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times\nat the agency have fluctuated in recent years as a result. In addition, government funding of the SEC, and other government agencies\non which our operations may rely, including those that fund research and development activities is subject to the political process,\nwhich is inherently fluid and unpredictable.\n\n \n\nDisruptions\nat the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies,\nwhich would adversely affect our business. For example, in recent years, the U.S. government shut down and certain regulatory agencies,\nsuch as the FDA and the SEC, had to furlough critical employees and stop critical activities. If a prolonged government shutdown continues\nto occur, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have\na material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets\nand obtain necessary capital in order to properly capitalize and continue our operations.\n\n \n\nIf\na prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting\ntheir regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory\nauthorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.\n\n \n\nSeparately,\nthe risk factor from our Annual Report on Form 10-K for the year ended June 30, 2025, titled “*Our common stock has been suspended\nfrom trading on the NYSE American. If we fail to regain compliance with the NYSE American listing standards, our common stock may be\ndelisted from the NYSE American*”, is no longer a material risk to the Company, as the Company resumed trading on the NYSE American\neffective November 12, 2025."}